Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology

Fig. 3

Characteristics of the corrected hiPSCs clones. A The expression level of pluripotent markers (OCT4, SOX2 and NANOG) in corrected hiPSC clones was analyzed by qRT-PCR. The gene-corrected clones maintained pluripotent genes. B Teratomas formation assay showed the differential ability of the corrected hiPSCs clones. C The expression of OCT4 and SOX2 in β41-42/β41-42 and αα/ααWS hiPSCs and βN/βN&αα/αα_corrected hiPSCs were detected by immunostaining. Scale bars = 100 µm. D, Karyotype analysis of the corrected hiPSCs clones showed that corrected hiPSCs retained normal female karyotype

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512